Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2023

Tianjiao LI; Longyun YE; Kaizhou JIN; Weiding WU; Xianjun YU

doi:10.19401/j.cnki.1007-3639.2024.01.001

您当前的位置：

首页 >

文章列表页 >

Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2023

Specialist' Commentary | 更新时间：2025-12-31

- Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2023
- China Oncology Vol. 34, Issue 1, Pages: 1-12(2024)
- 作者机构：
  
  复旦大学附属肿瘤医院胰腺外科，复旦大学上海医学院肿瘤学系，复旦大学胰腺肿瘤研究所，上海市胰腺肿瘤研究所，上海 200032
- 作者简介：
- 基金信息：
  
  National Natural Science Foundation of China(U21A20374)
- DOI：10.19401/j.cnki.1007-3639.2024.01.001
  CLC： R735.9
- Received：25 December 2023，
  
  Revised：2024-01-03，
  
  Published：30 January 2024
- 稿件说明：
移动端阅览
Tianjiao LI, Longyun YE, Kaizhou JIN, et al. Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2023[J]. China Oncology, 2024, 34(1): 1-12.
DOI：

Tianjiao LI, Longyun YE, Kaizhou JIN, et al. Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2023[J]. China Oncology, 2024, 34(1): 1-12. DOI： 10.19401/j.cnki.1007-3639.2024.01.001.

摘要

胰腺癌是恶性程度极高的消化系统肿瘤，其症状隐匿、治疗手段有限、进展迅速。随着胰腺癌的发病率逐年上升，胰腺癌越来越成为危害公共健康的突出问题，造成了巨大的社会负担。尽管胰腺癌患者的生存率在最近20余年并无明显改善，但目前在胰腺癌领域中，流行病学、基础和临床研究明显加速，有些研究成果已使一小部分胰腺癌患者取得更好的生存获益。本文就2023年度胰腺癌研究及诊疗的重大进展进行综述。

Abstract

Pancreatic cancer is a highly malignant digestive tract tumor with hidden symptoms

limited treatment options and rapid progression. With an increasing incidence rate year by year

pancreatic cancer has increasingly become a prominent issue endangering public health

causing a huge social burden. Although there was no significant improvement in survival rates for pancreatic cancer patients in the past two decades

recent progress in epidemiology

basic research and clinical research of pancreatic cancer has accelerated significantly compared to the past. Some findings have already enabled a small proportion of pancreatic cancer patients to achieve better survival. This article provided a review of the significant progress made in research

diagnosis and treatment of pancreatic cancer in 2023.

关键词

Keywords

references

SIEGEL R L , MILLER K D , WAGLE N S , et al . Cancer statistics, 2023 [J ] . CA A Cancer J Clinicians , 2023 , 73 ( 1 ): 17 - 48 . DOI: 10.3322/caac.v73.1 http://doi.org/10.3322/caac.v73.1 https://acsjournals.onlinelibrary.wiley.com/toc/15424863/73/1 https://acsjournals.onlinelibrary.wiley.com/toc/15424863/73/1

WANG Y A , YAN Q J , FAN C M , et al . Overview and countermeasures of cancer burden in China [J ] . Sci China Life Sci , 2023 , 66 ( 11 ): 2515 - 2526 . DOI: 10.1007/s11427-022-2240-6 http://doi.org/10.1007/s11427-022-2240-6

JU W , ZHENG R , ZHANG S , et al . Cancer statistics in Chinese older people, 2022: current burden, time trends, and comparisons with the US, Japan, and the Republic of Korea [J ] . Sci China Life Sci , 2023 , 66 ( 5 ): 1079 - 1091 . DOI: 10.1007/s11427-022-2218-x http://doi.org/10.1007/s11427-022-2218-x

HE S Y , XIA C F , LI H , et al . Cancer profiles in China and comparisons with the USA: a comprehensive analysis in the incidence, mortality, survival, staging, and attribution to risk factors [J ] . Sci China Life Sci , 2023 : 1 - 10 .

HALBROOK C J , LYSSIOTIS C A , PASCA DI MAGLIANO M , et al . Pancreatic cancer: advances and challenges [J ] . Cell , 2023 , 186 ( 8 ): 1729 - 1754 . DOI: 10.1016/j.cell.2023.02.014 http://doi.org/10.1016/j.cell.2023.02.014

CARPENTER E S , ELHOSSINY A M , KADIYALA P , et al . Analysis of donor pancreata defines the transcriptomic signature and microenvironment of early neoplastic lesions [J ] . Cancer Discov , 2023 , 13 ( 6 ): 1324 - 1345 . DOI: 10.1158/2159-8290.CD-23-0013 http://doi.org/10.1158/2159-8290.CD-23-0013 https://aacrjournals.org/cancerdiscovery/article/13/6/1324/726992/Analysis-of-Donor-Pancreata-Defines-the https://aacrjournals.org/cancerdiscovery/article/13/6/1324/726992/Analysis-of-Donor-Pancreata-Defines-the

ZHAO Y , TANG J , JIANG K , et al . Liquid biopsy in pancreatic cancer-current perspective and future outlook [J ] . Biochim Biophys Acta Rev Cancer , 2023 , 1878 ( 3 ): 188868 . DOI: 10.1016/j.bbcan.2023.188868 http://doi.org/10.1016/j.bbcan.2023.188868 https://linkinghub.elsevier.com/retrieve/pii/S0304419X23000173 https://linkinghub.elsevier.com/retrieve/pii/S0304419X23000173

GAO Q , LIN Y P , LI B S , et al . Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies [J ] . Ann Oncol , 2023 , 34 ( 5 ): 486 - 495 . DOI: 10.1016/j.annonc.2023.02.010 http://doi.org/10.1016/j.annonc.2023.02.010 https://linkinghub.elsevier.com/retrieve/pii/S092375342300087X https://linkinghub.elsevier.com/retrieve/pii/S092375342300087X

HAAN D , BERGAMASCHI A , FRIEDL V , et al . Epigenomic blood-based early detection of pancreatic cancer employing cell-free DNA [J ] . Clin Gastroenterol Hepatol , 2023 , 21 ( 7 ): 1802 - 1809 .e6. DOI: 10.1016/j.cgh.2023.03.016 http://doi.org/10.1016/j.cgh.2023.03.016 https://linkinghub.elsevier.com/retrieve/pii/S1542356523002240 https://linkinghub.elsevier.com/retrieve/pii/S1542356523002240

CHEN P T , WU T H , WANG P C , et al . Pancreatic cancer detection on CT scans with deep learning: a nationwide population-based study [J ] . Radiology , 2023 , 306 ( 1 ): 172 - 182 . DOI: 10.1148/radiol.220152 http://doi.org/10.1148/radiol.220152 http://pubs.rsna.org/doi/10.1148/radiol.220152 http://pubs.rsna.org/doi/10.1148/radiol.220152

LI X Y , GUO R , LU J , et al . Causality-driven graph neural network for early diagnosis of pancreatic cancer in non-contrast computerized tomography [J ] . IEEE Trans Med Imaging , 2023 , 42 ( 6 ): 1656 - 1667 . DOI: 10.1109/TMI.2023.3236162 http://doi.org/10.1109/TMI.2023.3236162 https://ieeexplore.ieee.org/document/10015096/ https://ieeexplore.ieee.org/document/10015096/

KORFIATIS P , SUMAN G , PATNAM N G , et al . Automated artificial intelligence model trained on a large data set can detect pancreas cancer on diagnostic computed tomography scans as well as visually occult preinvasive cancer on prediagnostic computed tomography scans [J ] . Gastroenterology , 2023 , 165 ( 6 ): 1533 - 1546 .e4. DOI: 10.1053/j.gastro.2023.08.034 http://doi.org/10.1053/j.gastro.2023.08.034 https://linkinghub.elsevier.com/retrieve/pii/S0016508523049582 https://linkinghub.elsevier.com/retrieve/pii/S0016508523049582

STOFFEL E M , BRAND R E , GOGGINS M . Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention [J ] . Gastroenterology , 2023 , 164 ( 5 ): 752 - 765 . DOI: 10.1053/j.gastro.2023.02.012 http://doi.org/10.1053/j.gastro.2023.02.012 https://linkinghub.elsevier.com/retrieve/pii/S0016508523001488 https://linkinghub.elsevier.com/retrieve/pii/S0016508523001488

PARTYKA O , PAJEWSKA M , KWAŚNIEWSKA D , et al . Overview of pancreatic cancer epidemiology in Europe and recommendations for screening in high-risk populations [J ] . Cancers (Basel) , 2023 , 15 ( 14 ): 3634 . DOI: 10.3390/cancers15143634 http://doi.org/10.3390/cancers15143634 https://www.mdpi.com/2072-6694/15/14/3634 https://www.mdpi.com/2072-6694/15/14/3634

PLACIDO D , YUAN B , HJALTELIN J X , et al . A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories [J ] . Nat Med , 2023 , 29 ( 5 ): 1113 - 1122 . DOI: 10.1038/s41591-023-02332-5 http://doi.org/10.1038/s41591-023-02332-5

RAUT P , NIMMAKAYALA R K , BATRA S K , et al . Clinical and molecular attributes and evaluation of pancreatic cystic neoplasm [J ] . Biochim Biophys Acta Rev Cancer , 2023 , 1878 ( 1 ): 188851 . DOI: 10.1016/j.bbcan.2022.188851 http://doi.org/10.1016/j.bbcan.2022.188851 https://linkinghub.elsevier.com/retrieve/pii/S0304419X22001767 https://linkinghub.elsevier.com/retrieve/pii/S0304419X22001767

POLLINI T , WONG P , MAKER A V . The landmark series: intraductal papillary mucinous neoplasms of the pancreas-from prevalence to early cancer detection [J ] . Ann Surg Oncol , 2023 , 30 ( 3 ): 1453 - 1462 . DOI: 10.1245/s10434-022-12870-w http://doi.org/10.1245/s10434-022-12870-w

NIKIFOROVA M N , WALD A I , SPAGNOLO D M , et al . A combined DNA/RNA-based next-generation sequencing platform to improve the classification of pancreatic cysts and early detection of pancreatic cancer arising from pancreatic cysts [J ] . Ann Surg , 2023 , 278 ( 4 ): e789 - e797 . DOI: 10.1097/SLA.0000000000005904 http://doi.org/10.1097/SLA.0000000000005904

TANAKA M , FERNÁNDEZ-DEL CASTILLO C , KAMISAWA T , et al . Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas [J ] . Pancreatology , 2017 , 17 ( 5 ): 738 - 753 . DOI: S1424-3903(17)30516-1 http://doi.org/S1424-3903(17)30516-1

VEGE S S , ZIRING B , JAIN R , et al . American Gastroenterological Association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts [J ] . Gastroenterology , 2015 , 148 ( 4 ): 819 - 822 ; quize12 - 13 . DOI: 10.1053/j.gastro.2015.01.015 http://doi.org/10.1053/j.gastro.2015.01.015

ZHANG X F , MAO T B , ZHANG B , et al . Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer [J ] . EBioMedicine , 2022 , 77 : 103897 . DOI: 10.1016/j.ebiom.2022.103897 http://doi.org/10.1016/j.ebiom.2022.103897 https://linkinghub.elsevier.com/retrieve/pii/S2352396422000810 https://linkinghub.elsevier.com/retrieve/pii/S2352396422000810

STRICKLER J H , SATAKE H , GEORGE T J , et al . Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer [J ] . N Engl J Med , 2023 , 388 ( 1 ): 33 - 43 . DOI: 10.1056/NEJMoa2208470 http://doi.org/10.1056/NEJMoa2208470 http://www.nejm.org/doi/10.1056/NEJMoa2208470 http://www.nejm.org/doi/10.1056/NEJMoa2208470

HALLIN J , BOWCUT V , CALINISAN A , et al . Anti-tumor efficacy of a potent and selective non-covalent KRAS G12D inhibitor [J ] . Nat Med , 2022 , 28 ( 10 ): 2171 - 2182 . DOI: 10.1038/s41591-022-02007-7 http://doi.org/10.1038/s41591-022-02007-7

MAHADEVAN K K , MCANDREWS K M , LEBLEU V S , et al . KRAS G12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS -mediated killing by CD8 + T cells [J ] . Cancer Cell , 2023 , 41 ( 9 ): 1606 - 1620 .e8. DOI: 10.1016/j.ccell.2023.07.002 http://doi.org/10.1016/j.ccell.2023.07.002 https://linkinghub.elsevier.com/retrieve/pii/S1535610823002428 https://linkinghub.elsevier.com/retrieve/pii/S1535610823002428

KEMP S B , CHENG N , MARKOSYAN N , et al . Efficacy of a small-molecule inhibitor of Kras G12D in immunocompetent models of pancreatic cancer [J ] . Cancer Discov , 2023 , 13 ( 2 ): 298 - 311 . DOI: 10.1158/2159-8290.CD-22-1066 http://doi.org/10.1158/2159-8290.CD-22-1066 https://aacrjournals.org/cancerdiscovery/article/13/2/298/716288/Efficacy-of-a-Small-Molecule-Inhibitor-of-KrasG12D https://aacrjournals.org/cancerdiscovery/article/13/2/298/716288/Efficacy-of-a-Small-Molecule-Inhibitor-of-KrasG12D

SINGH H , KELLER R B , KAPNER K S , et al . Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer [J ] . Clin Cancer Res , 2023 , 29 ( 22 ): 4627 - 4643 . DOI: 10.1158/1078-0432.CCR-22-3930 http://doi.org/10.1158/1078-0432.CCR-22-3930 https://aacrjournals.org/clincancerres/article/29/22/4627/729969/Oncogenic-Drivers-and-Therapeutic-Vulnerabilities https://aacrjournals.org/clincancerres/article/29/22/4627/729969/Oncogenic-Drivers-and-Therapeutic-Vulnerabilities

GOODWIN C M , WATERS A M , KLOMP J E , et al . Combination therapies with CDK4/6 inhibitors to treat KRAS -mutant pancreatic cancer [J ] . Cancer Res , 2023 , 83 ( 1 ): 141 - 157 .

STOSSEL C , RAITSES-GUREVICH M , ATIAS D , et al . Spectrum of response to platinum and PARP inhibitors in germline BRCA -associated pancreatic cancer in the clinical and preclinical setting [J ] . Cancer Discov , 2023 , 13 ( 8 ): 1826 - 1843 . DOI: 10.1158/2159-8290.CD-22-0412 http://doi.org/10.1158/2159-8290.CD-22-0412 https://aacrjournals.org/cancerdiscovery/article/13/8/1826/728136/Spectrum-of-Response-to-Platinum-and-PARP https://aacrjournals.org/cancerdiscovery/article/13/8/1826/728136/Spectrum-of-Response-to-Platinum-and-PARP

PATTERSON-FORTIN J , JADHAV H , PANTELIDOU C , et al . Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA -deficient cancer [J ] . Nat Commun , 2023 , 14 ( 1 ): 1390 . DOI: 10.1038/s41467-023-37096-6 http://doi.org/10.1038/s41467-023-37096-6

MANDELKER D , MARRA A , ZHENG-LIN B B , et al . Genomic profiling reveals germline predisposition and homologous recombination deficiency in pancreatic acinar cell carcinoma [J ] . J Clin Oncol , 2023 , 41 ( 33 ): 5151 - 5162 . DOI: 10.1200/JCO.23.00561 http://doi.org/10.1200/JCO.23.00561 https://ascopubs.org/doi/10.1200/JCO.23.00561 https://ascopubs.org/doi/10.1200/JCO.23.00561

YE L , SHI S , CHEN W . Innate immunity in pancreatic cancer: lineage tracing and function [J ] . Front Immunol , 2022 , 13 : 1081919 . DOI: 10.3389/fimmu.2022.1081919 http://doi.org/10.3389/fimmu.2022.1081919 https://www.frontiersin.org/articles/10.3389/fimmu.2022.1081919/full https://www.frontiersin.org/articles/10.3389/fimmu.2022.1081919/full

LV G , ZHANG L , GAO L , et al . The application of single-cell sequencing in pancreatic neoplasm: analysis, diagnosis and treatment [J ] . Br J Cancer , 2023 , 128 ( 2 ): 206 - 218 . DOI: 10.1038/s41416-022-02023-x http://doi.org/10.1038/s41416-022-02023-x

CHEN Y J , LI G N , LI X J , et al . Targeting IRG1 reverses the immunosuppressive function of tumor-associated macrophages and enhances cancer immunotherapy [J ] . Sci Adv , 2023 , 9 ( 17 ): eadg0654 . DOI: 10.1126/sciadv.adg0654 http://doi.org/10.1126/sciadv.adg0654 https://www.science.org/doi/10.1126/sciadv.adg0654 https://www.science.org/doi/10.1126/sciadv.adg0654

ZUO C , BAER J M , KNOLHOFF B L , et al . Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunotherapy [J ] . J Exp Med , 2023 , 220 ( 6 ): e20212062 . DOI: 10.1084/jem.20212062 http://doi.org/10.1084/jem.20212062 https://rupress.org/jem/article/220/6/e20212062/213966/Stromal-and-therapy-induced-macrophage https://rupress.org/jem/article/220/6/e20212062/213966/Stromal-and-therapy-induced-macrophage

ALONSO-NOCELO M , RUIZ-CAÑAS L , SANCHO P , et al . Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma [J ] . Gut , 2023 , 72 ( 2 ): 345 - 359 . DOI: 10.1136/gutjnl-2021-325564 http://doi.org/10.1136/gutjnl-2021-325564 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2021-325564 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2021-325564

CARONNI N , LA TERZA F , VITTORIA F M , et al . IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer [J ] . Nature , 2023 , 623 ( 7986 ): 415 - 422 . DOI: 10.1038/s41586-023-06685-2 http://doi.org/10.1038/s41586-023-06685-2

LIU X , TANG R , XU J , et al . CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma [J ] . Gut , 2023 , 72 ( 12 ): 2329 - 2343 . DOI: 10.1136/gutjnl-2022-329349 http://doi.org/10.1136/gutjnl-2022-329349 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2022-329349 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2022-329349

WANG L W , LIU Y H , DAI Y T , et al . Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment [J ] . Gut , 2023 , 72 ( 5 ): 958 - 971 . DOI: 10.1136/gutjnl-2021-326070 http://doi.org/10.1136/gutjnl-2021-326070 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2021-326070 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2021-326070

BIANCHI A N , DE CASTRO SILVA I , DESHPANDE N U , et al . Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer [J ] . Cancer Discov , 2023 , 13 ( 6 ): 1428 - 1453 . DOI: 10.1158/2159-8290.CD-22-1046 http://doi.org/10.1158/2159-8290.CD-22-1046

TINTELNOT J , XU Y , LESKER T R , et al . Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer [J ] . Nature , 2023 , 615 ( 7950 ): 168 - 174 . DOI: 10.1038/s41586-023-05728-y http://doi.org/10.1038/s41586-023-05728-y

ZOU X , GUAN C , GAO J , et al . Tertiary lymphoid structures in pancreatic cancer: a new target for immunotherapy [J ] . Front Immunol , 2023 , 14 : 1222719 . DOI: 10.3389/fimmu.2023.1222719 http://doi.org/10.3389/fimmu.2023.1222719 https://www.frontiersin.org/articles/10.3389/fimmu.2023.1222719/full https://www.frontiersin.org/articles/10.3389/fimmu.2023.1222719/full

KINKER G S , VITIELLO G A F , DINIZ A B , et al . Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas [J ] . Gut , 2023 , 72 ( 10 ): 1927 - 1941 . DOI: 10.1136/gutjnl-2022-328697 http://doi.org/10.1136/gutjnl-2022-328697 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2022-328697 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2022-328697

ZOU X , LIN X , CHENG H , et al . Characterization of intratumoral tertiary lymphoid structures in pancreatic ductal adenocarcinoma: cellular properties and prognostic significance [J ] . J Immunother Cancer , 2023 , 11 ( 6 ): e006698 . DOI: 10.1136/jitc-2023-006698 http://doi.org/10.1136/jitc-2023-006698 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2023-006698 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2023-006698

LIU X , HOGG G D , ZUO C , et al . Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity [J ] . Cancer Cell , 2023 , 41 ( 6 ): 1073 - 1090 .e12. DOI: 10.1016/j.ccell.2023.04.018 http://doi.org/10.1016/j.ccell.2023.04.018

HE F , TAY A H M , CALANDIGARY A , et al . FPR2 shapes an immune-excluded pancreatic tumor microenvironment and drives T-cell exhaustion in a sex-dependent manner [J ] . Cancer Res , 2023 , 83 ( 10 ): 1628 - 1645 . DOI: 10.1158/0008-5472.CAN-22-2932 http://doi.org/10.1158/0008-5472.CAN-22-2932

ROHILA D , PARK I H , PHAM T V , et al . Syk inhibition reprograms tumor-associated macrophages and overcomes gemcitabine-induced immunosuppression in pancreatic ductal adenocarcinoma [J ] . Cancer Res , 2023 , 83 ( 16 ): 2675 - 2689 . DOI: 10.1158/0008-5472.CAN-22-3645 http://doi.org/10.1158/0008-5472.CAN-22-3645

LEE Y E , GO G Y , KOH E Y , et al . Synergistic therapeutic combination with a CAF inhibitor enhances CAR-NK-mediated cytotoxicity via reduction of CAF-released IL-6 [J ] . J Immunother Cancer , 2023 , 11 ( 2 ): e006130 . DOI: 10.1136/jitc-2022-006130 http://doi.org/10.1136/jitc-2022-006130 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2022-006130 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2022-006130

WANG X D , SU S Y , ZHU Y Q , et al . Metabolic Reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors [J ] . Nat Commun , 2023 , 14 ( 1 ): 5778 . DOI: 10.1038/s41467-023-41470-9 http://doi.org/10.1038/s41467-023-41470-9

FU S N , XU S K , ZHANG S B . The role of amino acid metabolism alterations in pancreatic cancer: from mechanism to application [J ] . Biochim Biophys Acta Rev Cancer , 2023 , 1878 ( 3 ): 188893 . DOI: 10.1016/j.bbcan.2023.188893 http://doi.org/10.1016/j.bbcan.2023.188893 https://linkinghub.elsevier.com/retrieve/pii/S0304419X23000422 https://linkinghub.elsevier.com/retrieve/pii/S0304419X23000422

REBELO A , KLEEFF J , SUNAMI Y . Cholesterol metabolism in pancreatic cancer [J ] . Cancers (Basel) , 2023 , 15 ( 21 ): 5177 . DOI: 10.3390/cancers15215177 http://doi.org/10.3390/cancers15215177 https://www.mdpi.com/2072-6694/15/21/5177 https://www.mdpi.com/2072-6694/15/21/5177

PARK S J , YOO H C , AHN E , et al . Enhanced glutaminolysis drives hypoxia-induced chemoresistance in pancreatic cancer [J ] . Cancer Res , 2023 , 83 ( 5 ): 735 - 752 . DOI: 10.1158/0008-5472.CAN-22-2045 http://doi.org/10.1158/0008-5472.CAN-22-2045

NWOSU Z C , WARD M H , SAJJAKULNUKIT P , et al . Uridine-derived ribose fuels glucose-restricted pancreatic cancer [J ] . Nature , 2023 , 618 ( 7963 ): 151 - 158 . DOI: 10.1038/s41586-023-06073-w http://doi.org/10.1038/s41586-023-06073-w

CHEN M , CEN K L , SONG Y J , et al . NUSAP1-LDHA-Glycolysis-Lactate feedforward loop promotes Warburg effect and metastasis in pancreatic ductal adenocarcinoma [J ] . Cancer Lett , 2023 , 567 : 216285 . DOI: 10.1016/j.canlet.2023.216285 http://doi.org/10.1016/j.canlet.2023.216285 https://linkinghub.elsevier.com/retrieve/pii/S0304383523002367 https://linkinghub.elsevier.com/retrieve/pii/S0304383523002367

BARTMAN C R , WEILANDT D R , SHEN Y H , et al . Slow TCA flux and ATP production in primary solid tumours but not metastases [J ] . Nature , 2023 , 614 ( 7947 ): 349 - 357 . DOI: 10.1038/s41586-022-05661-6 http://doi.org/10.1038/s41586-022-05661-6

SCHUURMANS M , ALVES N , VENDITTELLI P , et al . Artificial intelligence in pancreatic ductal adenocarcinoma imaging: a commentary on potential future applications [J ] . Gastroenterology , 2023 , 165 ( 2 ): 309 - 316 . DOI: 10.1053/j.gastro.2023.04.003 http://doi.org/10.1053/j.gastro.2023.04.003 https://linkinghub.elsevier.com/retrieve/pii/S0016508523005863 https://linkinghub.elsevier.com/retrieve/pii/S0016508523005863

BIAN Y , ZHENG Z , FANG X , et al . Artificial intelligence to predict lymph node metastasis at CT in pancreatic ductal adenocarcinoma [J ] . Radiology , 2023 , 306 ( 1 ): 160 - 169 . DOI: 10.1148/radiol.220329 http://doi.org/10.1148/radiol.220329 http://pubs.rsna.org/doi/10.1148/radiol.220329 http://pubs.rsna.org/doi/10.1148/radiol.220329

ZHANG C Y , XU J , TANG R , et al . Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment [J ] . J Hematol Oncol , 2023 , 16 ( 1 ): 114 . DOI: 10.1186/s13045-023-01514-5 http://doi.org/10.1186/s13045-023-01514-5

CORTI C , COBANAJ M , DEE E C , et al . Artificial intelligence in cancer research and precision medicine: applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care [J ] . Cancer Treat Rev , 2023 , 112 : 102498 . DOI: 10.1016/j.ctrv.2022.102498 http://doi.org/10.1016/j.ctrv.2022.102498 https://linkinghub.elsevier.com/retrieve/pii/S0305737222001748 https://linkinghub.elsevier.com/retrieve/pii/S0305737222001748

LIN Q , ZHENG S Y , YU X J , et al . Standard pancreatoduodenectomy versus extended pancreatoduodenectomy with modified retroperitoneal nerve resection in patients with pancreatic head cancer: a multicenter randomized controlled trial [J ] . Cancer Commun (Lond) , 2023 , 43 ( 2 ): 257 - 275 .

FARNELL M B , PEARSON R K , SARR M G , et al . A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma [J ] . Surgery , 2005 , 138 ( 4 ): 618 - 628 ; discussion 628-630. DOI: 10.1016/j.surg.2005.06.044 http://doi.org/10.1016/j.surg.2005.06.044 https://linkinghub.elsevier.com/retrieve/pii/S0039606005004125 https://linkinghub.elsevier.com/retrieve/pii/S0039606005004125

NIMURA Y , NAGINO M , TAKAO S , et al . Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: Long-term results of a Japanese multicenter randomized controlled trial [J ] . J Hepatobiliary Pancreat Sci , 2012 , 19 ( 3 ): 230 - 241 . DOI: 10.1007/s00534-011-0466-6 http://doi.org/10.1007/s00534-011-0466-6

JANG J Y , KANG M J , HEO J S , et al . A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer [J ] . Ann Surg , 2014 , 259 ( 4 ): 656 - 664 . DOI: 10.1097/SLA.0000000000000384 http://doi.org/10.1097/SLA.0000000000000384 https://journals.lww.com/00000658-201404000-00008 https://journals.lww.com/00000658-201404000-00008

WANG W , LOU W , XU Z , et al . Long-term outcomes of standard versus extended lymphadenectomy in pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a Chinese multi-center prospective randomized controlled trial [J ] . J Adv Res , 2023 , 49 : 151 - 157 .

MEIERHOFER C , FUEGGER R , BIEBL M , et al . Pancreatic fistulas: current evidence and strategy-a narrative review [J ] . J Clin Med , 2023 , 12 ( 15 ): 5046 . DOI: 10.3390/jcm12155046 http://doi.org/10.3390/jcm12155046 https://www.mdpi.com/2077-0383/12/15/5046 https://www.mdpi.com/2077-0383/12/15/5046

GIULIANI T , PERRI G , KANG R , et al . Current perioperative care in pancreatoduodenectomy: a step-by-step surgical roadmap from first visit to discharge [J ] . Cancers (Basel) , 2023 , 15 ( 9 ): 2499 . DOI: 10.3390/cancers15092499 http://doi.org/10.3390/cancers15092499 https://www.mdpi.com/2072-6694/15/9/2499 https://www.mdpi.com/2072-6694/15/9/2499

VAN DEN BROEK B L J , ZWART M J W , BONSING B A , et al . Video grading of pancreatic anastomoses during robotic pancreatoduodenectomy to assess both learning curve and the risk of pancreatic fistula [J ] . Ann Surg , 2023 , 278 ( 5 ): e1048 - e1054 . DOI: 10.1097/SLA.0000000000005796 http://doi.org/10.1097/SLA.0000000000005796 https://journals.lww.com/10.1097/SLA.0000000000005796 https://journals.lww.com/10.1097/SLA.0000000000005796

SCHOUTEN T J , HENRY A C , SMITS F J , et al . Risk models for developing pancreatic fistula after pancreatoduodenectomy: validation in a nationwide prospective cohort [J ] . Ann Surg , 2023 , 278 ( 6 ): 1001 - 1008 . DOI: 10.1097/SLA.0000000000005824 http://doi.org/10.1097/SLA.0000000000005824 https://journals.lww.com/10.1097/SLA.0000000000005824 https://journals.lww.com/10.1097/SLA.0000000000005824

SCHUH F , MIHALJEVIC A L , PROBST P , et al . A simple classification of pancreatic duct size and texture predicts postoperative pancreatic fistula: a classification of the international study group of pancreatic surgery [J ] . Ann Surg , 2023 , 277 ( 3 ): e597 - e608 . DOI: 10.1097/SLA.0000000000004855 http://doi.org/10.1097/SLA.0000000000004855 https://journals.lww.com/10.1097/SLA.0000000000004855 https://journals.lww.com/10.1097/SLA.0000000000004855

STOOP T F , BERGQUIST E , THEIJSE R T , et al . Systematic review and meta-analysis of the role of total pancreatectomy as an alternative to pancreatoduodenectomy in patients at high risk for postoperative pancreatic fistula: is it a justifiable indication? [J ] . Ann Surg , 2023 , 278 ( 4 ): e702 - e711 . DOI: 10.1097/SLA.0000000000005895 http://doi.org/10.1097/SLA.0000000000005895

ELLIS R J , BRAJCICH B C , BERTENS K A , et al . Association between biliary pathogens, surgical site infection, and pancreatic fistula: results of a randomized trial of perioperative antibiotic prophylaxis in patients undergoing pancreatoduodenectomy [J ] . Ann Surg , 2023 , 278 ( 3 ): 310 - 319 . DOI: 10.1097/SLA.0000000000005955 http://doi.org/10.1097/SLA.0000000000005955

SPRINGFELD C , FERRONE C R , KATZ M H G , et al . Neoadjuvant therapy for pancreatic cancer [J ] . Nat Rev Clin Oncol , 2023 , 20 ( 5 ): 318 - 337 . DOI: 10.1038/s41571-023-00746-1 http://doi.org/10.1038/s41571-023-00746-1

VERSTEIJNE E , VAN DAM J L , SUKER M , et al . Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial [J ] . J Clin Oncol , 2022 , 40 ( 11 ): 1220 - 1230 . DOI: 10.1200/JCO.21.02233 http://doi.org/10.1200/JCO.21.02233 https://ascopubs.org/doi/10.1200/JCO.21.02233 https://ascopubs.org/doi/10.1200/JCO.21.02233

MOTOI F , KOSUGE T , UENO H , et al . Randomized phase Ⅱ/Ⅲ trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05) [J ] . Jpn J Clin Oncol , 2019 , 49 ( 2 ): 190 - 194 . DOI: 10.1093/jjco/hyy190 http://doi.org/10.1093/jjco/hyy190 https://academic.oup.com/jjco/article/49/2/190/5272732 https://academic.oup.com/jjco/article/49/2/190/5272732

YAMAGUCHI J , YOKOYAMA Y , FUJII T , et al . Results of a phase Ⅱ study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01) [J ] . Ann Surg , 2022 , 275 ( 6 ): 1043 - 1049 . DOI: 10.1097/SLA.0000000000005430 http://doi.org/10.1097/SLA.0000000000005430 https://journals.lww.com/10.1097/SLA.0000000000005430 https://journals.lww.com/10.1097/SLA.0000000000005430

GHANEH P , PALMER D , CICCONI S , et al . Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial [J ] . Lancet Gastroenterol Hepatol , 2023 , 8 ( 2 ): 157 - 168 . DOI: 10.1016/S2468-1253(22)00348-X http://doi.org/10.1016/S2468-1253(22)00348-X https://linkinghub.elsevier.com/retrieve/pii/S246812532200348X https://linkinghub.elsevier.com/retrieve/pii/S246812532200348X

SMAGLO B G . Role for neoadjuvant systemic therapy for potentially resectable pancreatic cancer [J ] . Cancers (Basel) , 2023 , 15 ( 8 ): 2377 . DOI: 10.3390/cancers15082377 http://doi.org/10.3390/cancers15082377 https://www.mdpi.com/2072-6694/15/8/2377 https://www.mdpi.com/2072-6694/15/8/2377

SEUFFERLEIN T , UHL W , KORNMANN M , et al . Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase Ⅱ trial of the AIO pancreatic cancer group [J ] . Ann Oncol , 2023 , 34 ( 1 ): 91 - 100 . DOI: 10.1016/j.annonc.2022.09.161 http://doi.org/10.1016/j.annonc.2022.09.161 https://linkinghub.elsevier.com/retrieve/pii/S0923753422041849 https://linkinghub.elsevier.com/retrieve/pii/S0923753422041849

SUGAWARA T , RODRIGUEZ FRANCO S , SHERMAN S , et al . Association of adjuvant chemotherapy in patients with resected pancreatic adenocarcinoma after multiagent neoadjuvant chemotherapy [J ] . JAMA Oncol , 2023 , 9 ( 3 ): 316 - 323 . DOI: 10.1001/jamaoncol.2022.5808 http://doi.org/10.1001/jamaoncol.2022.5808 https://jamanetwork.com/journals/jamaoncology/fullarticle/2799187 https://jamanetwork.com/journals/jamaoncology/fullarticle/2799187

WAINBERG Z A , MELISI D , MACARULLA T , et al . NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial [J ] . Lancet , 2023 , 402 ( 10409 ): 1272 - 1281 . DOI: 10.1016/S0140-6736(23)01366-1 http://doi.org/10.1016/S0140-6736(23)01366-1

HILMI M , DELAYE M , MUZZOLINI M , et al . The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy [J ] . Lancet Gastroenterol Hepatol , 2023 , 8 ( 12 ): 1129 - 1142 . DOI: 10.1016/S2468-1253(23)00207-8 http://doi.org/10.1016/S2468-1253(23)00207-8 https://linkinghub.elsevier.com/retrieve/pii/S2468125323002078 https://linkinghub.elsevier.com/retrieve/pii/S2468125323002078

CHEN I M , DONIA M , CHAMBERLAIN C A , et al . Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R) [J ] . Eur J Cancer , 2023 , 180 : 125 - 133 . DOI: 10.1016/j.ejca.2022.11.035 http://doi.org/10.1016/j.ejca.2022.11.035

BENDELL J , LORUSSO P , OVERMAN M , et al . First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors [J ] . Cancer Immunol Immunother , 2023 , 72 ( 7 ): 2443 - 2458 . DOI: 10.1007/s00262-023-03430-6 http://doi.org/10.1007/s00262-023-03430-6

KO A H , KIM K P , SIVEKE J T , et al . Atezolizumab plus PEGPH20 versus chemotherapy in advanced pancreatic ductal adenocarcinoma and gastric cancer: MORPHEUS phase Ⅰb/Ⅱ umbrella randomized study platform [J ] . Oncologist , 2023 , 28 ( 6 ): 553 - e472 . DOI: 10.1093/oncolo/oyad022 http://doi.org/10.1093/oncolo/oyad022 https://academic.oup.com/oncolo/article/28/6/553/7081215 https://academic.oup.com/oncolo/article/28/6/553/7081215

LEMECH C , DREDGE K , BAMPTON D , et al . Phase Ⅰb open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors [J ] . J Immunother Cancer , 2023 , 11 ( 1 ): e006136 . DOI: 10.1136/jitc-2022-006136 http://doi.org/10.1136/jitc-2022-006136 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2022-006136 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2022-006136

ROJAS L A , SETHNA Z , SOARES K C , et al . Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer [J ] . Nature , 2023 , 618 ( 7963 ): 144 - 150 . DOI: 10.1038/s41586-023-06063-y http://doi.org/10.1038/s41586-023-06063-y

ZHU H , WEI M , XU J , et al . PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications [J ] . Mol Cancer , 2020 , 19 ( 1 ): 49 . DOI: 10.1186/s12943-020-01167-9 http://doi.org/10.1186/s12943-020-01167-9

NEVALA-PLAGEMANN C , HIDALGO M , GARRIDO-LAGUNA I . From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer [J ] . Nat Rev Clin Oncol , 2020 , 17 ( 2 ): 108 - 123 . DOI: 10.1038/s41571-019-0281-6 http://doi.org/10.1038/s41571-019-0281-6

NAGASAKA M , POTUGARI B , NGUYEN A , et al . KRAS inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond [J ] . Cancer Treat Rev , 2021 , 101 : 102309 . DOI: 10.1016/j.ctrv.2021.102309 http://doi.org/10.1016/j.ctrv.2021.102309 https://linkinghub.elsevier.com/retrieve/pii/S0305737221001572 https://linkinghub.elsevier.com/retrieve/pii/S0305737221001572

WOOD L D , CANTO M I , JAFFEE E M , et al . Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment [J ] . Gastroenterology , 2022 , 163 ( 2 ): 386 - 402 .e1. DOI: 10.1053/j.gastro.2022.03.056 http://doi.org/10.1053/j.gastro.2022.03.056 https://linkinghub.elsevier.com/retrieve/pii/S0016508522003560 https://linkinghub.elsevier.com/retrieve/pii/S0016508522003560

QIAN Y , GONG Y , FAN Z , et al . Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma [J ] . J Hematol Oncol , 2020 , 13 ( 1 ): 130 . DOI: 10.1186/s13045-020-00958-3 http://doi.org/10.1186/s13045-020-00958-3

SCHULTHEIS B , REUTER D , EBERT M P , et al . Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase Ⅱb study [J ] . Ann Oncol , 2017 , 28 ( 10 ): 2429 - 2435 . DOI: 10.1093/annonc/mdx343 http://doi.org/10.1093/annonc/mdx343 https://linkinghub.elsevier.com/retrieve/pii/S0923753419349476 https://linkinghub.elsevier.com/retrieve/pii/S0923753419349476

QIN S K , LI J , BAI Y X , et al . Nimotuzumab plus gemcitabine for K - ras wild-type locally advanced or metastatic pancreatic cancer [J ] . J Clin Oncol , 2023 , 41 ( 33 ): 5163 - 5173 . DOI: 10.1200/JCO.22.02630 http://doi.org/10.1200/JCO.22.02630 https://ascopubs.org/doi/10.1200/JCO.22.02630 https://ascopubs.org/doi/10.1200/JCO.22.02630

SHAIB W L , MANALI R , LIU Y , et al . Phase Ⅱ randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198) [J ] . Eur J Cancer , 2023 , 189 : 112847 . DOI: 10.1016/j.ejca.2023.02.030 http://doi.org/10.1016/j.ejca.2023.02.030 https://linkinghub.elsevier.com/retrieve/pii/S0959804923001284 https://linkinghub.elsevier.com/retrieve/pii/S0959804923001284

HUFFMAN B M , BASU MALLICK A , HORICK N K , et al . Effect of a MUC5AC antibody (NPC-1C) administered with second-line gemcitabine and nab-paclitaxel on the survival of patients with advanced pancreatic ductal adenocarcinoma: a randomized clinical trial [J ] . JAMA Netw Open , 2023 , 6 ( 1 ): e2249720 . DOI: 10.1001/jamanetworkopen.2022.49720 http://doi.org/10.1001/jamanetworkopen.2022.49720 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2800079 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2800079

RODON AHNERT J , TAN D S , GARRIDO-LAGUNA I , et al . Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ⅰb of the JAVELIN PARP MEKi trial [J ] . ESMO Open , 2023 , 8 ( 4 ): 101584 . DOI: 10.1016/j.esmoop.2023.101584 http://doi.org/10.1016/j.esmoop.2023.101584 https://linkinghub.elsevier.com/retrieve/pii/S2059702923008177 https://linkinghub.elsevier.com/retrieve/pii/S2059702923008177

Views

6366

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

New advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2024

Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2021

Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2018

Recent advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2017

Recent advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2016

Related Author

Ting WANG

Yi QIN

Xiaowu XU

Xianjun YU

Xinzhe ZHU

Hao LI

Huaxiang XU

Guopei LUO

Related Institution

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai Pancreatic Cancer Institute, Shanghai Key Laboratory of Precision Medicine for Pancreatic Cancer, Pancreatic Cancer Institute, Fudan University

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University; Pancreatic Cancer Institute, Fudan University; Shanghai Pancreatic Cancer Institute

复旦大学附属肿瘤医院胰腺外科，复旦大学胰腺肿瘤研究所，上海市胰腺肿瘤研究所，复旦大学上海医学院肿瘤学系

复旦大学附属肿瘤医院胰腺外科、胰腺癌研究所，复旦大学上海医学院肿瘤学系

Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

AI问答

⁰